By Daily Nation
People with psychiatric disorders may want to pass on the joint — at least until further research is done, a new Australian study suggests.
The paper, published Monday in The Lancet Psychiatry, looked at 83 previous studies conducted over almost four decades on medical cannabinoids, including products from the cannabis plant, such as leaves, buds and oils, as well as pharmaceutical-grade cannabinoids.
The authors found insufficient evidence that the products were safe and effective in treating six common disorders: depression, anxiety, attention-deficit hyperactivity disorder, Tourette syndrome, post-traumatic stress disorder and psychosis.
Cannabis and cannabinoids are increasingly being made available for medicinal use in North America, Britain and Australia without being subjected to the standard process that includes testing and scrutinizing by government regulatory bodies, lead author Louisa Degenhardt told AFP.
Engage with us on LinkedIn: Africa Sustainability Matters
